DR. STEPHEN PLYMATE, M.D.
Osteopathic Medicine in Seattle, WA
License number
Washington MD00018159
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
1660 S COLUMBIAN WAY, Seattle, WA 98108
Phone
(206) 762-1010
(206) 824-4666
(206) 824-4666
Personal information
See more information about STEPHEN PLYMATE at radaris.comName
Address
Phone
24935 8Th Pl S, Seattle, WA 98198
24935 8Th St, Seattle, WA 98198
8623 46Th St, Seattle, WA 98136
Organization information
See more information about STEPHEN PLYMATE at bizstanding.comStephen Plymate MD
325 9 Ave, Seattle, WA 98104
Industry:
Internist
Phone:
(206) 731-4191 (Phone)
Stephen Rex Plymate
Professional information
See more information about STEPHEN PLYMATE at trustoria.com
Stephen R Plymate, Seattle WA
Stephen R Plymate, Seattle WA
Specialties:
Endocrinologist
Address:
325 9Th Ave, Seattle, WA 98104
1660 S Columbian Way, Seattle, WA 98108
1660 S Columbian Way, Seattle, WA 98108
Education:
University of Nebraska, College of Medicine - Doctor of Medicine
University of Washington Medical Center - Fellowship - Endocrinology
Madigan Army Medical Center - Residency - Family Medicine
University of Washington Medical Center - Fellowship - Endocrinology
Madigan Army Medical Center - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Dr. Stephen Plymate, Seattle WA - MD (Doctor of Medicine)
Dr. Stephen Plymate, Seattle WA - MD (Doctor of Medicine)
Specialties:
Geriatric Medicine, Endocrinology & Metabolism, Endocrinology, Diabetes & Metabolism
Address:
325 9Th Ave SUITE 359625, Seattle 98104
(206) 341-4504 (Phone)
1660 S Columbian Way, Seattle 98108
(206) 762-1010 (Phone)
(206) 341-4504 (Phone)
1660 S Columbian Way, Seattle 98108
(206) 762-1010 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1973, Geriatric Medicine, 1994, Internal Medicine, 1972
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
325 9Th Ave SUITE 359625, Seattle 98104
1660 S Columbian Way, Seattle 98108
Harborview Medical Center
325 9Th Ave, Seattle 98104
1660 S Columbian Way, Seattle 98108
Harborview Medical Center
325 9Th Ave, Seattle 98104
Education:
Medical School
University of Nebraska / College of Medicine
Graduated: 1968
Madigan Army Medical Center
University Of Washington
University of Nebraska / College of Medicine
Graduated: 1968
Madigan Army Medical Center
University Of Washington
Igf-Ir Antagonists As Adjuvants For Treatment Of Prostate Cancer
Igf-Ir Antagonists As Adjuvants For Treatment Of Prostate Cancer
US Patent:
2009017, Jul 9, 2009
Filed:
Feb 5, 2007
Appl. No.:
11/702838
Inventors:
Dale L. Ludwig - Randolph NJ, US
Stephen R. Plymate - Des Moines WA, US
Stephen R. Plymate - Des Moines WA, US
International Classification:
A61K 39/395, A61K 31/7088, A61K 38/22
US Classification:
4241381, 514 44, 514 12
Abstract:
The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
Receptor Antagonists For Treatment Of Metastatic Bone Cancer
Receptor Antagonists For Treatment Of Metastatic Bone Cancer
US Patent:
2009011, Apr 30, 2009
Filed:
Jun 19, 2006
Appl. No.:
11/917890
Inventors:
Dale L. Ludwig - Randolph NJ, US
Stephen R. Plymate - Des Moines WA, US
Stephen R. Plymate - Des Moines WA, US
Assignee:
ImClone Systems Incorporated - New York NY
University of Washington - Seattle WA
University of Washington - Seattle WA
International Classification:
A61K 39/395, A61P 35/00, A61K 31/337, A61K 31/704, C12N 15/13, C12N 15/63, C12N 5/10, C12N 1/19
US Classification:
4241331, 4241301, 4241361, 514449, 514 34, 4241781, 536 2353, 4353201, 435325, 435358, 435365, 4353721, 4352542
Abstract:
The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.